United States Securities And Exchange Commission
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): January 30, 2019

 

Isoray, Inc.
(Exact name of registrant as specified in its charter)

  

Delaware
(State or other jurisdiction
of incorporation)

001-33407
(Commission
File Number)

41-1458152
(IRS Employer
Identification No.)

 

350 Hills Street, Suite 106, Richland, Washington 99354

(Address of principal executive offices) (Zip Code)

 

(509) 375-1202

(Registrant ’s telephone number, including area code)

IsoRay, Inc

(Former name, former address and former fiscal year, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following p r ovisions:

 

 

 

Written  communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

   

 

 

Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

   

 

 

Pre-commencement  communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

   

 

 

Pre-commencement  communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item  1.01      Entry into a Material Definitive Agreement.

 

The information set forth under Item 5.02 of this Current Report on Form 8-K is incorporated into this Item 1.01 by reference.

 

 Item  1.02      Termination of a Material Definitive Agreement.

 

The information set forth under Item 5.02 of this Current Report on Form 8-K is incorporated into this Item 1.02 by reference.

 

On February 6, 2019, the Employment Agreement dated March 7, 2016, between Isoray, Inc. (the “Company”) and Michael Krachon was terminated by virtue of the Company and Mr. Krachon entering into the Employment Agreement described in Item 5.02 below.  Pursuant to the 2016 Employment Agreement, Mr. Krachon served as Vice President of Sales and Marketing at an annual salary of $225,000.  There were no early termination penalties incurred by the Company in connection with the termination.

 

Item  2.02      Results of Operations and Financial Condition .

 

On February 12, 2019 , the Company issued a press release announcing its financial results for the second quarter of fiscal 2019 ended December 31, 2018, the text of which is attached hereto as Exhibit 99.1.

 

The information in this item of this Current Report on Form 8-K, including the exhibits, is furnished pursuant to Item  2.02 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

Item 5.02       Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

Executive Employment Agreement

 

On February 6, 2019, the Company entered into an Employment Agreement with Michael Krachon, in his position as Vice President, Sales and Marketing. This agreement supersedes and replaces the Employment Agreement with Mr. Krachon dated March 7, 2016.

 

The initial term of the Employment Agreement is three years, subject to successive one year renewals. Mr. Krachon will receive an annual salary of $243,337.50, all payable in accordance with the Company’s standard payroll practices. Mr. Krachon will be eligible for a quarterly and an annual discretionary bonus as periodically established by the Compensation Committee based upon metrics that will be established by the Compensation Committee in its sole discretion. Also under the Employment Agreement, Mr. Krachon is eligible to participate in and receive stock options under the Company’s 2017 Equity Incentive Plan.

 

Mr. Krachon will be an “at-will” employee. Either Mr. Krachon or the Company may terminate the Executive’s employment with or without cause, for any reason or no reason, and at any time. If Mr. Krachon is terminated without cause or at will, he will be entitled to receive six months’ severance based on his then current base salary.

 

Mr. Krachon is subject to standard confidentiality provisions and a non-compete, non-solicitation covenant for a one-year period following termination of his employment. 

 

The above descriptions are only a summary of the material terms of the Employment Agreement, do not purport to be complete descriptions of the Employment Agreement, and are qualified in their entirety by reference to the Employment Agreement, the form of which is filed as Exhibit 10.1 and incorporated herein by reference.

 

Item  8.01      Other Events .

 

On January 30, 2019 , the Company issued a press release announcing that it will be holding a teleconference to discuss its financial results for the second quarter of fiscal 2019 ended December 31, 2018, the text of which is attached hereto as Exhibit 99.2.

 

I tem 9.01       Financial Statements and Exhibits .

 

(d)       Exhibits

 

  10.1 Employment Agreement between Isoray, Inc. and Michael Krachon, dated effective February 6, 2019.
 

99.1

Press release issued by Isoray, Inc., dated February 12, 2019.

  99.2 Press release issued by Isoray, Inc., dated January 30, 2019.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 12, 2019

 

Isoray, Inc., a Delaware corporation

 

 

 

By: /s/ Lori A. Woods           

       Lori A. Woods, CEO

Exhibit 10.1

 

Employment Agreement

 

This Employment Agreement (“ Agreement ”) is made in the State of Washington by and between Michael Krachon (“ E xecutive ”) and Isoray, Inc. a Delaware corporation (the “ Company ”).

 

WHEREAS, the Company is engaged in the business of providing innovative solutions for the treatment of malignancies using medical isotopes (the “ Business ”); and

 

WHEREAS, the parties desire that the Company retain Executive under the terms and conditions set forth in this Agreement; and

 

WHEREAS, the Company and Executive intend that this Agreement will supersede and replace the March 7, 2016 Employment Agreement and any and all other employment agreements entered into by and between the Company and Executive, and that upon execution of this Agreement, any such employment agreements or arrangements shall have no further force or effect, except the confidentiality provisions (Section 6) and Schedule 1 in the March 7, 2016 Employment Agreement between the parties executed prior to this Agreement which shall continue in full force and effect; and

 

WHEREAS, the parties desire to express their mutual agreements, covenants, promises, and understandings in a written agreement;

 

NOW THEREFORE, in consideration of the premises and the agreements, promises, covenants, and provisions contained in this Agreement, the parties agree and declare as follows:

 

1.      Employment. The Company hereby employs Executive and Executive accepts employment under the terms and conditions of this Agreement.

 

2.      Position and Duties .

 

(a)     Executive will faithfully and diligently serve the Company to the best of his ability in his position as Vice President of Sales and Marketing and in the performance of such other duties and responsibilities as the Company may assign to him.

 

(b)     Executive will devote his full professional time, attention, and energies to the performance of his duties for the Company, and will not, during his employment under this Agreement, engage in any other business activity, whether or not for profit, except for passive investments in firms or businesses that do not compete with the Company, without the advance written and signed consent of the Company. Notwithstanding this Section 2 (b) , Executive will be permitted to serve as a director of not for profit and for profit businesses that do not compete with the Company.

 

(c)     Executive warrants that during the term of his employment under this Agreement, he will not do any act or engage in any conduct, or permit, condone, or acquiesce in any act or conduct of other persons, that he knew or should have known could cause the Company to be in violation of any law or statute, and Executive agrees to indemnify and hold the Company harmless against any and all liabilities, claims, damages, fees, losses, and expenses of any kind or nature whatsoever attributable directly or indirectly to a violation of this warranty.

 

 

 

 

(d)     The Company acknowledges that Employee’s principal place of residence is Atlanta, Georgia and that the Company shall not require Employee to relocate his principal place of residence in furtherance of his employment; provided, however, that Employee agrees and acknowledges that Employee will be expected to travel to Company locations regularly as part of his duties. More specifically, the Company may impose a minimum number of days Employee shall be required to spend in Richland, Washington, subject to Employee’s consent if greater than five (5) days per month.

 

(e)     Executive agrees to comply with the policies and procedures of the Company as may be adopted and changed from time to time, including without limitation, those described in the Company’s employee handbook, Code of Ethics for Chief Executive Officer & Senior Financial Officers, and Code of Conduct and Ethics. If this Agreement conflicts with such policies or procedures, this Agreement will control.

 

(f)     As an officer of the Company, Executive owes a duty of care and loyalty to the Company as well as a duty to perform such duties in a manner that is in the best interests of the Company.

 

3.      Compensation and Benefits . For and in consideration of all services rendered under this Agreement, the Company will compensate Executive as follows:

 

(a)      Salary. During the term of Executive’s employment under this Agreement, Executive will be compensated on the basis of an annual salary of $243,337.50, payable in accord with the Company’s standard payroll practices. Executive may be eligible for an increase of his annual salary as determined by the Compensation Committee and based upon metrics that will be established by the Compensation Committee in its sole discretion.

 

(b)      Bonus. In addition to Executive’s base salary ( Section 3 (a) ), throughout his employment, Executive will be eligible for a quarterly and an annual discretionary bonus as periodically established by the Compensation Committee (the “ Bonus ”), based upon metrics that will be established by the Compensation Committee in its sole discretion paid at the time periods determined by the Compensation Committee.

 

(c)      Stock Options. Executive shall be eligible to participate in and receive stock options as defined by the relevant equity incentive plan.

 

(d)      Expenses. The Company will reimburse Executive for all reasonable and necessary expenses that Executive incurs in carrying out his duties under this Agreement in accordance with the Company reimbursement policies as in effect from time to time, provided that Executive presents to the Company from time to time an itemized account of such expenses in such form as the Company may require.

 

(e)      Paid Time Off. Executive is entitled to unlimited Paid Time Off (“PTO”), as long as Executive fulfills his job duties. Such paid time shall include time off for sickness, vacation, or personal reasons. The time or times during which leave may be taken shall be by mutual agreement of the Company and Executive. Whenever possible, the Company agrees to accommodate and grant Executive’s request for time. Since Executive does not accrue PTO, the Company will not compensate for any PTO upon termination of the Agreement.

 

-2-

 

 

(f)      Participation in Benefit Plans. As of the Effective Date, Executive shall be included in any and all plans of the Company providing general benefits for the Company’s employees, including, without limitation, medical, dental, vision, disability, life insurance, 401(k) plan, and holidays.

 

4.      Term/Termination Of Employment .

 

(a)      Initial Term . Executive’s employment under this Agreement commenced on February 6, 2019, but this Agreement will be effective as of February 6, 2019 (“ Effective Date ”), and will continue for a period of three (3) years (the “ Initial Term ”). Thereafter, this Agreement shall renew only upon thirty (30) days written notice as provided in Section 4 (b) .

 

(b)      Renewal . Upon at least thirty (30) days written notice by the Company prior to the end of the Initial Term, and subject to the provisions for termination set forth below, the term of Executive’s employment under this Agreement will extend thereafter for a period of one year (the “ Renewal Term ”). Upon the expiration of such subsequent term and any term renewed hereunder, and subject to the provisions for termination set forth below, the term of Executive’s employment under this Agreement will require thirty (30) days written notice of renewal by the Company for each successive Renewal Term of one-year.

 

(c)      Employment At Will. Notwithstanding Sections 4 (b) and 4 (b) , Executive understands and agrees that this Agreement does not create an obligation on the part of the Company or any other person or entity to continue Executive’s employment. Executive acknowledges and agrees that he is an at-will employee of the Company, which means that either party to this Agreement may terminate Executive’s employment with or without cause, for any or no reason and at any time. Executive’s employment shall also be deemed terminated upon Executive’s death or becoming disabled.

 

(d)      Termination. Notwithstanding the at will employment relationship defined in Section 4(c), the Agreement may be terminated by:

 

(i)     Expiration of the Initial Term or any Renewal Term without further renewal of the term;

 

(ii)     Mutual written agreement between Executive and the Company at any time;

 

(iii)     The Company For Cause as defined in Section 4 ( e ) below;

 

(iv)     Resignation by Executive at will and without notice;

 

-3-

 

 

(v)     Termination without cause or at will, which shall mean any termination of employment by the Company which is not defined in this Section 4 ( d )(i) through Section 4 (c)( i v) ;

 

(vi)     Resignation by Executive with 60-days’ written notice to the CEO; or

 

(vii)     Termination of Executive by the New Company that occurs concurrently with a Change in Control, as provided by Section 11.

 

(e)      Termination For Cause. The Company may terminate Executive’s employment under this Agreement immediately upon the occurrence of any of the following events (each, a “For Cause” termination):

 

(i)     Executive’s gross inattention to or neglect of, or gross negligence or incompetence in the performance of, duties assigned to him under this Agreement;

 

(ii)     Executive’s acceptance of any other employment;

 

(iii)     Executive’s conviction by a court of or plea of guilty or nolo contendere to fraud, dishonesty, or other acts of misconduct in rendering services on behalf of the Company;

 

(iv)     Any deliberate or unauthorized action or omission by Executive that causes or may cause the Company to breach obligations under any contract; or

 

(v)     Executive’s material breach of any covenant, promise, provision, or obligation of this Agreement.

 

5.      Company’s Post-Termination Obligations.

 

(a)     If Executive’s employment terminates for any of the reasons set forth in Sections 4(d)(i), 4(d)(ii), 4(d)(iii), 4(d)(iv), and 4(d)(vi) above, then the Company will pay Executive (1) all accrued but unpaid wages, based on Executive’s then current base salary, through the termination date; and (2) all approved, but unreimbursed, business expenses, provided that a request for reimbursement of business expenses is submitted in accordance with the Company’s policies and submitted within five (5) business days of Executive’s termination date. Amounts payable pursuant to this Section 5 shall be paid within the time required by the state of Washington.

 

(b)     If the Company terminates Executive’s employment for the reason set forth in Section 4(d)(v) above, then the Company will: (1) pay Executive all accrued but unpaid wages through the termination date, based on Executive’s then current base salary, through the termination date; (2) reimburse all approved, but unreimbursed, business expenses, provided that a request for reimbursement of business expenses is submitted in accordance with the Company’s policies and submitted within five (5) business days of Executive’s termination date; (3) pay Executive six (6) months’ severance, based on Executive’s then current base salary, to be paid out in accordance with the Company’s regular payroll practices; and (4) pay COBRA premiums for up to 6 months of coverage, if Executive elects to continue health insurance coverage under COBRA, unless and until Executive becomes eligible for health insurance coverage through outside employment. To exercise this right to severance under this Section 5(b), Executive must sign a separation agreement pursuant to Section 5(d), below.

 

-4-

 

 

(c)     At a Change in Control (Section 11), if Executive’s is not retained by the New Company, as set forth in Section 4(d)(vii) above, then the Company will: (1) pay Executive all accrued but unpaid wages through the termination date, based on Executive’s then current base salary, through the termination date; (2) reimburse all approved, but unreimbursed, business expenses, provided that a request for reimbursement of business expenses is submitted in accordance with the Company’s policies and submitted within five (5) business days of Executive’s termination date; (3) pay Executive twelve (12) months’ severance, based on Executive’s then current base salary, to be paid out in accordance with the Company’s regular payroll practices, provided that Executive signs a separation agreement pursuant to Section 5(d), below. To exercise this right to severance under this Section 5(c), Executive must be employed by the Company on the date of the Change in Control (Section 11).

 

(d)     The Company’s obligation to provide the payments set forth in Section 5 ( b ) and Section 5 ( c ) above shall be conditioned upon the following (the “Separation Conditions”):

 

(i)     Executive’s execution of a separation agreement, in a form prepared by the Company and within 21 days of receiving the separation agreement, which will include a general release from liability so that Executive will release the Company and its Subsidiaries from any and all liability and claims of any kind as permitted by law; and

 

(ii)     Executive’s compliance with the restrictive covenants ( Sections 6 - 9 ) and all post-termination obligations, including, but not limited to, the obligations contained in this Agreement.

 

(iii)     If Executive refuses to execute (or revokes) an effective separation agreement as set forth in Section 5 ( d ) (i) above prior to the expiration of the 21-day period (or if any applicable revocation period has not yet ended prior to such time), the Company will not provide any payments or benefits to Executive under Section 5 ( b ) and Section 5(c) until such separation agreement is executed and becomes effective. The Company’s obligation to make the separation payments set forth in Section 5(b ) and Section 5(c) shall terminate immediately upon any breach by Executive of any post-termination obligations to which Executive is subject.

 

(iv)     Except as provided in Sections 5(b) and (c) above, following termination of Executive’s employment, the Company shall have no other obligations for compensation of Executive.

 

(e)      Set-Off . If Executive has any outstanding obligations to the Company upon the termination of Executive’s employment for any reason, Executive hereby authorizes the Company to deduct any amounts owed to the Company from Executive’s final paycheck and/or any amounts that would otherwise be due to Executive, including under Section 5 , but only to the extent such set-off is made in accordance with Treasury Regulation 1.409A-3(j)(4)(xiii). No other set-off shall be permitted under this Agreement.

 

-5-

 

 

6.      Confidential Commercial Information .

 

(a)     Executive acknowledges that he will be entrusted with price lists, customer lists, customer contact information, information about customer transactions, development and research work, marketing programs, plans, and proposals, and data contained within internally employed software, data bases, and computer operations developed by or for the Company (“ Confidential Commercial Information ”); provided, however, that for the purposes of this Agreement Confidential Commercial Information does not include information (i) that was publicly available prior to Executive’s disclosure or use thereof; or (ii) that Executive lawfully received from some person who was not under any obligation of confidentiality with respect thereto; (iii) that becomes publicly available other than as the result of any breach of this Agreement by Executive; or (iv) that is generally known to or readily ascertainable by proper means by other persons who can obtain economic value from its disclosure or use. Executive acknowledges that Confidential Commercial Information derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use, and that the Company has made efforts that are reasonable under the circumstances to maintain the secrecy of Confidential Commercial Information.

 

(b)     Executive acknowledges that he has been instructed by the Company to, and agrees that he will, maintain the Company’s Confidential Commercial Information in a confidential manner. During his employment, Executive will not, directly or indirectly, disclose any Confidential Commercial Information to any person or entity not authorized by the Company to receive or use such Confidential Commercial Information. After the termination of Executive’s employment, for whatever reason and by whatever party, Executive will not, directly or indirectly, use or disclose to any person or entity any Confidential Commercial Information without the prior written authorization of the Company.

 

(c)     All documents and other tangible property relating in any way to the business of the Company that Executive develops or that come into his possession during his employment are the property of the Company, and Executive will return all such documents and tangible property to the Company upon the termination of his employment, or at such earlier time as the Company may request.

 

(d)     Executive acknowledges that all of the commercially available software that the Company uses on its computer system that was not developed specially by or for the Company is either owned or licensed for use by the Company, and that the use of such software is governed strictly by the explicit terms and conditions of licensing agreements between the Company and the publisher of the software, and Executive agrees to adhere to those terms and conditions. Executive will not copy, duplicate, download, transfer, or otherwise make personal use of any software on the Company’s computer system without the Company’s express, written consent.

 

-6-

 

 

(e)     Executive represents that to the best of his knowledge, the performance of all the terms of this Agreement and of his duties as an employee of the Company will not breach any agreement to keep in confidence any proprietary information that he acquired in confidence prior to his employment under this Agreement, and that Executive has not entered into, and agrees that he will not enter into, any agreement either written or oral in conflict with this Agreement. Executive represents that to the best of his knowledge, Executive has not brought and will not bring to the Company or use in the performance of his responsibilities at the Company any materials or documents of a former employer that are not generally available to the public, unless Executive has obtained express written authorization from the former employer for their possession and use. Executive represents that he has delivered to the Company a true and correct copy of any employment, proprietary information, confidentiality, or non-competition agreement to which he is or was a party with any former employers, and that is or may be in effect as of the date hereof. Executive has been instructed not to breach any obligation of confidentiality that he may have to any former employer and agrees that he will not commit any such breach during employment with the Company.

 

7.      Inventions and Copyrights .

 

(a)     Executive acknowledges that, as a part of his duties, during his employment, he may develop discoveries, concepts, and ideas concerning or relating to the Business, whether or not patentable, including without limitation processes, methods, formulas, and techniques, as well as improvements thereof or know-how related thereto, and concerning any present or prospective activities of the Company that are published before such discoveries, concepts, and ideas (“ Inventions ”).

 

(b)     Executive will fully disclose and will continue to disclose to the Company all Inventions that he makes or conceives, in whole or in part, at this time or during his employment with the Company.

 

(c)     Any and all Inventions will be the absolute property of the Company or its designees and, at the request of the Company and at its expense, but without additional compensation, Executive will make application in due form for United States patents and foreign patents on such Inventions, and will assign to the Company all his right, title, and interest in such Inventions, and will execute any and all instruments and do any and all acts necessary or desirable in connection with any such application for patents or in order to establish and perfect in the Company the entire right, title, and interest in such Inventions, patent applications, or patents, and also execute any instrument necessary or desirable in connection with any continuations, renewals, or reissues thereof or in the conduct of any related proceedings or litigation.

 

(d)     The Company will own the copyright in all materials created by Executive relating to the Business and eligible for copyright (which will be deemed work made-for-hire). The Company will have the right to apply for copyright registration, including any renewals or extension, whether under the laws of the U.S. or any country having jurisdiction over the copyright. Executive agrees to execute any documents necessary or appropriate for such registration. The Company will also own any trademark, service mark or trade name created by Executive (alone or in conjunction with others) for the Company and used to identify any present or future product, service, activity, operation, or function of the Company. The Company may obtain trademark or service mark protection of the Company’s rights including, at the Company’s discretion, state, federal and international registration. The Company will own all right, title, and interest in and to all results and the work product of Executive’s services for the Company (all of which will be deemed proprietary), free of any reserved rights by Executive, whether or not specifically enumerated in this Agreement.

 

-7-

 

 

8.      Post-Employment Restrictions .

 

(a)     Following the termination of Executive’s employment, for whatever reason and by whatever party, and during any Restrictive Period, Executive will not, directly or indirectly, on his own behalf or on behalf of any other person or entity:

 

(i)     enter into or engage in any business that provides Competitive Products or Competitive Services within the Restricted Areas;

 

(ii)     solicit or accept orders for Competitive Products from any person or entity upon whom he called or with whom he had direct or indirect contact on behalf of the Company and who at the time of such conduct is a customer or client of the Company;

 

(iii)     solicit or accept orders for Competitive Products from any person or entity who was a customer or client of the Company during his engagement and who at the time of such conduct is a customer or client of the Company;

 

(iv)     solicit or accept orders for Competitive Products from any person or entity who at the time of such conduct is a customer or client of the Company;

 

(v)     encourage, entice, induce, or influence, directly or indirectly, any person or entity not to do business with the Company;

 

(vi)     encourage, entice, induce, or influence, directly or indirectly, any person to terminate his or his employment with the Company; or

 

(vii)     hire, retain, or offer to hire or retain for the performance of any service in connection with the marketing, distribution, or sale of any Competitive Product any person who at the time of such conduct is an employee of the Company or who was an employee of the Company within the 180-day prior to such conduct.

 

(b)     The Restrictive Periods are: (a) the 90-day period commencing on the termination of Executive’s employment with the Company (the “ First Restrictive Period ”); and (b) the 90-day period commencing on the expiration of the First Restrictive Period (the “ Second Restrictive Period ”); and (c) the 90-day period commencing on the expiration of the Second Restrictive Period (the “ Third Restrictive Period ”); and (d) the 90-day period commencing on the expiration of the Third Restrictive Period (the “ Fourth Restrictive Period ”).

 

(c)     The term of any Restrictive Period set forth in this Agreement will be tolled for any time during which Executive is in violation of any provision of this Agreement and for any time during which there is pending any action or arbitration (including any appeal from any final judgment) brought by any person, whether or not a party to this Agreement, in which action the Company seeks to enforce this Agreement or in which any person contests the validity of such agreements and covenants or their enforceability, or seeks to avoid their performance or enforcement.

 

-8-

 

 

(d)     “ Competitive Products ” means any supplies, equipment, products, goods, or services that are similar to or competitive with supplies, equipment, products, goods, or services that the Company marketed, distributed, or sold during Executive’s employment with the Company.

 

(e)     The “Restrictive Areas” are: (1) the area within a 10 air-mile radius of any location of the Company at which Executive performed services during his employment under this Agreement; and (2) Benton County, Washington; and (3) the state of Washington; and (5) the Mountain Time Zone and the Pacific Time Zone of the United States; and (6) that portion of the United States west of the Mississippi River; (7) the United States; and (8) any country in which the Company is conducting business at the time of Executive’s separation from employment.

 

9.      Non-Disparagement. Executive agrees that during the term of Executive’s services to the Company, and at any time thereafter, not to make or communicate any comments or other remarks which are negative or derogatory to the Company or which would tend to disparage, slander, ridicule, degrade, harm or injure the Company (or any business relationship of the Company) or any officer, partnership member, or other employee of the Company or its affiliates.

 

10.      Remedies .

 

(a)     The parties expressly agree that, in the event of any failure by the Company to pay any wages to which Executive may become entitled in connection with his employment in violation of RCW 49.48 et seq. , the amount of Executive’s recovery will be limited to the amount of actual wages that the court or arbitrator determines to have been unpaid, and, notwithstanding the provisions of RCW 49.48.125, no greater amount. Executive hereby expressly waives any remedy that he may have or that may later become available to his under RCW 49.48 et seq. for any additional amounts.

 

(b)     Any breach of the duties and obligations imposed upon Executive by this Agreement would cause irreparable harm to the Company, and the Company could not be fully compensated for any such breach with money damages. Therefore, injunctive relief is an appropriate remedy for any such breach. Such injunctive relief will be in addition to and not in limitation of or substitution for any other remedies or rights to which the Company may be entitled at law or in equity, including without limitation liquidated damages under this Agreement.

 

-9-

 

 

11.      Change of Control . Notwithstanding anything to the contrary in the Company’s existing or future incentive plans or any award agreement granted to Executive thereunder, upon a Change of Control, all of Executive’s outstanding unvested equity-based awards, at Executive’s option, shall vest and become immediately exercisable and unrestricted, without any action by the Board or any committee thereof. “ Change of Control ” shall mean the first of the following events to occur after the Effective Date:

 

(a)     a Person or one or more Persons acting as a group acquires ownership of stock of the Company that, together with the Company stock held by such person or group, constitutes more than fifty percent (50%) of the total fair market value or total voting power of the stock of the Company; or

 

(b)     the following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the Effective Date, constitute the Board and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for election by the Company’s stockholders was approved or recommended by a majority of the directors then still in office who either were directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended; and

 

(c)     a Person or one or more Persons acting as a group acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from the Company equal to or more than forty percent (40%) of the total gross fair market value of all of the assets of the Company determined immediately prior to such acquisition;

 

(d)     For purposes of this Section 11 ,

 

(i)     “ Person ” shall mean a “person” as defined in Section 7701(a)(1) of the Code, except that such term shall not include (A) the Company (or any Subsidiary thereof), (B) a trustee or other fiduciary holding securities under an employee benefit plan of the Company, (C) an underwriter temporarily holding securities pursuant to an offering of such securities, or (D) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

(ii)     Stock ownership shall be determined in accordance with the attribution rules of Section 318(a) of the Code.

 

(iii)     The gross fair market value of an asset shall be determined without regard to any liabilities associated with that asset.

 

(iv)     A “Change of Control” shall not be occur (A) by virtue of the consummation of any transaction or series of integrated transactions immediately following which the holders of the common stock of the Company immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Company immediately following such transaction or series of transactions, and (B) as a result of any primary or secondary offering of shares of the Company’s common stock or preferred stock to the general public through a registration statement filed with the Securities and Exchange Commission.

 

12.      Prevailing Party s Litigation Expenses. In the event of litigation between the Company and Executive related to this Agreement, the non-prevailing party shall reimburse the prevailing party for any costs and expenses (including, without limitation, attorneys’ fees) reasonably incurred by the prevailing party in connection therewith.

 

-10-

 

 

13.      Supersedes Previous Agreements. This Agreement constitutes the entire understanding between the Company and the Executive relating to the employment of the Executive by the Company and supersedes and cancels all prior written (specifically, the parties March 7, 2016 Employment Agreement, except the confidentiality provisions (section 6) and Schedule 1 therein) and oral agreements and understandings with respect to the subject matter of this Agreement.

 

14.      Withholding . All amounts payable to Executive hereunder shall be subject to required payroll deductions and tax withholdings.

 

15.      Adjudication of Agreement .

 

(a)     If any court or arbitrator of competent jurisdiction holds that any restriction imposed upon Executive by this Agreement exceeds the limit of restrictions that are enforceable under applicable law, the parties desire and agree that the restriction will apply to the maximum extent that is enforceable under applicable law, agree that the court or arbitrator so holding may reform and enforce the restriction to the maximum extent that is enforceable under applicable law, and desire and request that the court or arbitrator do so.

 

(b)     If any court or arbitrator of competent jurisdiction holds that any provision of this Agreement is invalid or unenforceable, the parties desire and agree that the remaining parts of this Agreement will nevertheless continue to be valid and enforceable.

 

16.      Modification Or Waiver Of Agreement. No modification or waiver of this Agreement will be valid unless the modification or waiver is in writing and signed by both of the parties. The failure of either party at any time to insist upon the strict performance of any provision of this Agreement will not be construed as a waiver of the right to insist upon the strict performance of the same provision at any future time.

 

17.      Notices. Any notices required or permitted under this Agreement will be sufficient if in writing and sent by certified mail to, in the case of Executive, the last address he has filed in writing with the Company or, in the case of the Company, its principal office.

 

18.      Opportunity To Consider Agreement; Legal Representation. Executive acknowledges that he has had a full opportunity to consider this Agreement, to offer suggested modifications to its terms and conditions, and to consult with an attorney of his own choosing before deciding whether to sign it.

 

19.      No Rule Of Strict Construction. The language of this Agreement has been approved by both parties, and no rule of strict construction will be applied against either party.

 

20.      Entire Agreement. This Agreement contains all of the agreements between the parties relating to Executive’s employment with the Company. The parties have no other agreements relating to Executive’s employment, written or oral. This Agreement supersedes all other agreements, arrangements, and understandings relating to Executive’s employment, and no such agreements, arrangements, or understandings are of any force or effect. The parties will execute and deliver to each other any and all such further documents and instruments, and will perform any and all such other acts, as reasonably may be necessary or proper to carry out or effect the purposes of this Agreement.

 

-11-

 

 

21.      Assignment Of Agreement. Executive has no right to transfer or assign any or all of his rights or interests under this Agreement. The Company may assign its rights and interests under this Agreement to any successor entity as part of any sale, transfer, or other disposition of all or substantially all of the assets of the Company.

 

22.      Headings. The descriptive headings of the paragraphs and subparagraphs of this Agreement are intended for convenience only, and do not constitute parts of this Agreement.

 

23.      Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

 

24.      Choice Of Forum. The parties agree that the proper and exclusive forum for any action or arbitration arising out of or relating to this Agreement or arising out of or relating to Executive’s employment by the Company will be Benton County, Washington, and that any such action or arbitration will be brought only in Benton County, Washington. Executive consents to the exercise of personal jurisdiction in any such action or arbitration by the courts or arbitrators of Benton County, Washington.

 

25.      Governing Law. This Agreement will be construed in accord with and any dispute or controversy arising from any breach or asserted breach of this Agreement will be governed by the laws of the State of Washington, without reference to the choice of law principles thereof.

 

[Signature Page follows]

 

-12-

 

 

Schedule 1

 

 

LIST OF PRIOR INVENTIONS

AND ORGINAL WORKS OF AUTHORSHIP

 

  Title Date Identifying Number or Brief Description

 

 

  Brachytherapy Seed Insertion WO 2014/189604
  And Fixation System  
     
     
  Bendable, shielding US 2014/0323795 A1
  Brachytherapy needle holder  

 

-13-

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement on the dates indicated at their respective signatures below.

 

  DATED this 6th day of February, 2019.
       
       
          /s/Michael Krachon
                     Michael Krachon
       
   
  DATED this 6th day of February, 2019.
       
    Isoray, Inc., a Delaware corporation
       
       
    By:    /s/Lori A. Woods
      Lori A. Woods
    Its: Chief Executive Officer

 

-14-

Exhibit 99.1

 

 

Isoray Announces Second Quarter Fiscal 2019 Financial Results

 

Record Revenue and Gross Profit
Revenue Increased 24% Year-Over-Year

 

RICHLAND, Wash., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the second quarter of fiscal 2019 ended December 31, 2018.

 

Revenue for the second quarter of fiscal 2019 grew 24% to a record $1.90 million versus $1.54 million in the prior year comparable period. The revenue increase was driven by 29% sales growth in the company’s core prostate brachytherapy offerings, which includes the recently launched Blu Build delivery system. Prostate brachytherapy represented 89% of total revenue for the second quarter of 2019 compared to 86% in the prior year comparable period. Non-prostate brachytherapy revenue in the quarter was comprised primarily of sales to treat brain and lung cancers. 

 

Gross profit as a percentage of revenues increased to a record 40.2% for the three months ended December 31, 2018 versus 34.6% in the prior year comparable period. Second quarter gross profit increased 44% to a record $0.77 million versus $0.53 million in the second quarter of fiscal 2018, largely attributed to increased sales and the company’s continued leverage of its facilities, personnel, and isotope.

 

Isoray CEO Lori Woods said, “We are pleased to report record revenue and gross profit this quarter. We have realized successes in growing our core business, achieving market share gains, and attracting new customers. We believe these important milestone achievements speak to what is ahead for Isoray as we continue to execute our plans for expanded market opportunities and growth.”

 

Total operating expenses in the second quarter were $2.2 million compared to $2.0 million in the prior year period. Total research and development expenses increased 22% versus the prior year comparable period. The increase in total research and development expenses was primarily the result of increases in proprietary product development expenses related to the Blu Build delivery system. Sales and marketing expenses increased 4% versus the prior year comparable period. General and administrative expenses increased 12% versus the prior year comparable period, primarily the result of an increase in headcount and expenses related to the company’s annual shareholder meeting.

 

The net loss for the three months ended December 31, 2018 was $1.41 million or ($0.02) per basic and diluted share versus a net loss of $1.46 million or ($0.03) per basic and diluted share in the comparable prior year period. Basic and diluted per share results are based on weighted average shares outstanding of approximately 67.3 million for the three months ended December 31, 2018 versus 55.1 million in the comparable prior year period.

 

For the first six months of fiscal 2019 ended December 31, 2018, revenue increased 26% to $3.47 million versus $2.75 million in the prior year comparable period. Prostate brachytherapy represented 89% of total revenue for the first half of fiscal 2019 compared to 87% for the first half of fiscal 2018. Total operating expenses for the first six months of fiscal 2019 increased 11% to $4.24 million, versus $3.82 million in the prior year comparable period. The net loss for the first half of fiscal 2019 was $2.92 million, or ($0.04) per basic and diluted share, compared to a net loss of $3.01 million, or ($0.05), per basic and diluted share in the prior year comparable period. Basic and diluted per share results are based on weighted average shares outstanding of approximately 66.7 million for the six months ended December 31, 2018 versus 55.0 million in the comparable prior year period.

 

Cash, cash equivalents, and certificates of deposit at the end of the second quarter of fiscal 2019 totaled $7.87 million and the company had no debt. 

 

Conference Call Details
The Company will hold an earnings conference call today, February 12, at 4:30 p.m. ET/1:30 p.m. PT to discuss operating results. To listen to the conference call, please dial (866) 682-6100. For callers outside the U.S., please dial (862) 298-0702.

 

The conference call will be simultaneously webcast and can be accessed at https://www.investornetwork.com/event/presentation/42028 by clicking on the link. The webcast will be available until May 12, 2019 following the conference call. A replay of the call will also be available by phone and can be accessed by dialing (877) 481-4010 and providing reference number 42028. For callers outside the U.S., please dial (919) 882-2331 and provide reference number 42028. The replay will be available beginning approximately 1 hour after the completion of the live event, ending at 4:30 p.m. Eastern Time on February 19, 2019.

 

Contacts
Investor Relations: Mark Levin (501) 255-1910
Media and Public Relations: Sharon Schultz (302) 539-3747

 

 

 

 

About Isoray
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting  www.isoray.com . Join us on Facebook and follow us on Twitter @Isoray .

 

Safe Harbor Statement
Statements in this news release about Isoray's future expectations, including: the advantages of our products and their delivery systems, whether interest in and use of our products will increase or continue, whether our new marketing strategy will continue to increase sales, whether use of Cesium-131 in non-prostate applications will continue to increase revenue, whether further manufacturing and production process improvements will be completed or will result in lower costs, whether our market presence and growth will continue, the timing of ongoing commercialization of GammaTile TM Therapy, the acceptance rate of our Blu Build delivery system, the positive industry data fueling renewed interest in brachytherapy, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released that support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards, the success of our sales and marketing efforts, changes in reimbursement rates, the procedures and regulatory requirements mandated by the FDA for 510(k) approval and reimbursement codes, changes in laws and regulations applicable to our products, the scheduling of physicians who either delay or do not schedule patients in periods anticipated, the use of competitors' products in lieu of our products, less favorable reimbursement rates than anticipated for each of our products, and other risks detailed from time to time in Isoray's reports filed with the SEC. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  

 

 

 

 

Isoray, Inc. and Subsidiaries

Consolidated Balance Sheets (Unaudited)

(In thousands, except shares)

 

   

December 31,

   

June 30,

 
   

2018

   

2018

 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 3,201     $ 2,600  

Short-term investments

    4,667       825  

Accounts receivable, net

    1,107       1,192  

Inventory

    494       494  

Prepaid expenses and other current assets

    351       335  
                 

Total current assets

    9,820       5,446  
                 

Property and equipment, net

    1,471       1,311  

Restricted cash

    181       181  

Inventory, non-current

    266       319  

Other assets, net of accumulated amortization

    173       198  
                 

Total assets

  $ 11,911     $ 7,455  
                 

LIABILITIES AND SHAREHOLDERS' EQUITY

               

Current liabilities:

               

Accounts payable and accrued expenses

  $ 1,196     $ 1,391  

Accrued protocol expense

    113       77  

Accrued radioactive waste disposal

    55       37  

Accrued payroll and related taxes

    120       155  

Accrued vacation

    156       175  
                 

Total current liabilities

    1,640       1,835  

Long-term liabilities:

               

Asset retirement obligation

    606       590  
                 

Total liabilities

    2,246       2,425  

Shareholders' equity:

               

Preferred stock, $.001 par value; 7,000,000 shares authorized:

               

Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding

    -       -  

Common stock, $.001 par value; 200,000,000 shares authorized; 67,331,147 and 56,331,147 shares issued and outstanding

    67       56  

Additional paid-in capital

    91,868       84,322  

Accumulated deficit

    (82,270

)

    (79,348

)

                 

Total shareholders' equity

    9,665       5,030  
                 

Total liabilities and shareholders' equity

  $ 11,911     $ 7,455  

 

 

 

 

Isoray, Inc. and Subsidiaries

Consolidated Statements of Operations (Unaudited)

(Dollars and shares in thousands, except for per-share amounts)

 

   

Three months ended

   

Six months ended

 
   

December 31,

   

December 31,

 
   

2018

   

2017

   

2018

   

2017

 
                                 

Product sales, net

  $ 1,904     $ 1,536     $ 3,466     $ 2,747  

Cost of product sales

    1,139       1,005       2,177       1,951  

Gross profit

    765       531       1,289       796  
                                 

Operating expenses:

                               

Research and development:

                               

Proprietary research and development

    395       311       789       597  

Collaboration arrangement, net of reimbursement

    19       29       45       104  

Total research and development

    414       340       834       701  

Sales and marketing

    702       674       1,351       1,288  

(Gain) on Equipment Disposal

    (23

)

    -       (23

)

    -  

General and administrative

    1,101       985       2,074       1,827  

Total operating expenses

    2,194       1,999       4,236       3,816  
                                 

Operating loss

    (1,429

)

    (1,468

)

    (2,947

)

    (3,020

)

                                 

Non-operating income:

                               

Interest income, net

    15       5       25       10  

Non-operating income, net

    15       5       25       10  
                                 

Net loss

    (1,414

)

    (1,463

)

    (2,922

)

    (3,010

)

Preferred stock dividends

    (2

)

    (3

)

    (5

)

    (5

)

                                 

Net loss applicable to common shareholders

  $ (1,416

)

  $ (1,466

)

  $ (2,927

)

  $ (3,015

)

                                 

Basic and diluted loss per share

  $ (0.02

)

  $ (0.03

)

  $ (0.04

)

  $ (0.05

)

                                 

Weighted average shares used in computing net loss per share:

                               

Basic and diluted

    67,331       55,056       66,743       55,037  

 

Exhibit 99.2

 

 

Isoray To Announce Second Quarter Fiscal 2019 Financial Results on February 12, 2019

 

Conference Call is February 12 at 4:30 p.m. ET/1:30 p.m. PT

 

RICHLAND, WASH., Jan. 30, 2019 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal 2019 ended December 31, 2018 on Tuesday, February 12, 2019, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the second quarter fiscal 2019 after the close of the U.S. stock markets on February 12, 2019. 

 

To listen to the conference call, please dial 866-682-6100. For callers outside the U.S., please dial 862-298-0702.

 

The conference call will be simultaneously webcast and can be accessed at https://www.investornetwork.com/event/presentation/42028 by clicking on the link. The webcast will be available until May 12, 2019 following the conference call. A replay of the call will also be available by phone and can be accessed by dialing 877-481-4010 and providing reference number 42028. For callers outside the U.S., please dial 919-882-2331 and provide reference number 42028. The replay will be available beginning approximately 1 hour after the completion of the live event, ending at 4:30 pm Eastern Time on February 19, 2019.

 

About Isoray
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting  www.isoray.com . Join us on  Facebook and follow us on Twitter @Isoray .

 

Contact

Investor Relations: Mark Levin (501) 255-1910

Media and Public Relations: Sharon Schultz (302) 539-3747